SGLT2 Inhibitors for Diabetes: Evidence and Outcomes

View Evidence Brief

Evidence on outcomes studied for SGLT2 Inhibitors

Evidence related to SGLT2 inhibitor therapies in diabetes studies.

Build your Evidence Workspace

Save evidence about the topics you care about.

Studies

100

Evidence Pairs

Moderate Evidence

Evidence Strength: 62/100

Evidence Intelligence™

Evidence Summary

A structured summary of where the evidence is strongest, mixed, or still emerging.

Executive Summary

SGLT2 Inhibitors evidence appears to center on HbA1c.

Among 32 indexed studies and 4 interventions, the strongest signals are summarized from the available evidence. HbA1c appears to be one of the clearer current evidence signals.

Evidence is consistently positive across multiple studies.
Some evidence is positive, but results are not consistent across all studies.
Early findings are encouraging, but stronger trials are needed.

Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Key Finding

Evidence is consistently positive across multiple studies.

Interventions with strongest consistent evidence

Strongest consistent evidence

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

HbA1c appears to have a consistent beneficial signal in the indexed evidence.

View supporting studies

Evidence basis: 13 evidence pairs - 22 studies

Why this appears here

Strong evidenceConsistent resultsPositive effect signalMultiple RCTsModerate evidence

HbA1c

18 studies

EvidenceScore™

85/100

ConsistencyScore™

74/100

Body weight

7 studies

EvidenceScore™

84/100

ConsistencyScore™

84/100

Evidence Snapshot

Studies

Interventions

Outcomes

Across 3 studies, Canagliflozin shows a moderate positive signal for HbA1c.

3 studies

EvidenceScore™: 79/100

View supporting studies

Supporting Evidence

Mixed or conflicting evidence

Some evidence is positive, but results are not consistent across all studies.

Areas where results are mixed

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

HbA1c is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Top entities

HbA1c

Fasting Plasma Glucose (FPG)

HbA1c

18 studies

EvidenceScore™

85/100

ConsistencyScore™

74/100

Why this appears here

Mixed Or Conflicting ResultsPositive Signal PresentNeutral Results Present

Evidence basis: 12 evidence pairs - 22 studies

View supporting studies

Promising but understudied

Early findings are encouraging, but stronger trials are needed.

Promising areas needing more evidence

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Systolic blood pressure may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Top entities

Systolic blood pressure

Triglycerides

Systolic blood pressure

4 studies

EvidenceScore™

75/100

ConsistencyScore™

73/100

Why this appears here

Positive effect signalLimited study volume

Evidence basis: 7 evidence pairs - 10 studies

View supporting studies

Question Highlights

Quick answers to the most important questions supported by the available evidence.

Explore all evidence questions

What outcomes has SGLT2 Inhibitors been studied for?

HbA1c, Body weight, and Fasting Plasma Glucose (FPG) are among the most studied areas in relation to SGLT2 Inhibitors.

HbA1c, Body weight, and Fasting Plasma Glucose (FPG) are among the best-supported options in the available evidence across 32 studies.

Consistency cannot yet be determined.

View full answer

Does SGLT2 Inhibitors improve HbA1c?

SGLT2 Inhibitors may improve HbA1c.

Strong evidence is based on 18 supporting studies.

Population details are unavailable.

View full answer

How does SGLT2 Inhibitors compare across studied outcomes?

HbA1c, Body weight, and Fasting Plasma Glucose (FPG) have available evidence for SGLT2 Inhibitors, but the comparison requires review of the underlying studies.

Evidence is available for both Body weight and Fasting Plasma Glucose (FPG); the underlying studies are needed for a direct comparison.

Population details are unavailable.

View full answer

Explore all evidence questions

Explore the Evidence

The sections below provide the complete evidence questions, supporting relationships, and underlying studies behind the summary above.

Questions Answered by the Evidence

What outcomes has SGLT2 Inhibitors been studied for?

outcomes studied

Emerging Evidence

HbA1c, Body weight, and Fasting Plasma Glucose (FPG) are among the most studied areas in relation to SGLT2 Inhibitors.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.4 | moderate positive | ConsistencyScore™ Consistent | 18 studies
2
Body weight
EvidenceScore™ Strong | EvidenceScore™ 83.8 | moderate positive | ConsistencyScore™ Consistent | 7 studies
3
Fasting Plasma Glucose (FPG)
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 8 studies

Why this answer: This answer is based on 32 supporting studies and existing graph evidence signals.

Limitations

Consistency cannot yet be determined.
Population details are unavailable.

Does SGLT2 Inhibitors improve HbA1c?

intervention outcome_effect

Strong Evidence

SGLT2 Inhibitors may improve HbA1c.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.4 | moderate positive | ConsistencyScore™ Consistent | 18 studies

Why this answer: This answer is based on 18 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

Does SGLT2 Inhibitors affect body weight?

intervention outcome_effect

Strong Evidence

SGLT2 Inhibitors may improve Body weight.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 83.8 | moderate positive | ConsistencyScore™ Consistent | 7 studies

Why this answer: This answer is based on 7 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

Which outcomes have the strongest evidence for SGLT2 Inhibitors?

evidence strength

Strong Evidence

HbA1c, Body weight, and Fasting Plasma Glucose (FPG) have the strongest available evidence signals for SGLT2 Inhibitors.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.4 | moderate positive | ConsistencyScore™ Consistent | 18 studies
2
Body weight
EvidenceScore™ Strong | EvidenceScore™ 83.8 | moderate positive | ConsistencyScore™ Consistent | 7 studies
3
Fasting Plasma Glucose (FPG)
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 8 studies

Why this answer: This answer is based on 20 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

Where does SGLT2 Inhibitors need more research?

research gaps

Moderate Evidence

Fasting blood sugar (FBS), Estimated glomerular filtration rate, and Heart failure hospitalizations need more research in relation to SGLT2 Inhibitors.

ConsistencyScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: Some evidence reported benefits while other evidence found little or no effect.

Ranked evidence signals

1
Fasting blood sugar (FBS)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 2 studies
2
Estimated glomerular filtration rate
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 2 studies
3
Liver stiffness measure
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 2 studies

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

Population details are unavailable.

How does SGLT2 Inhibitors compare across studied outcomes?

cross outcome_comparison

Strong Evidence

HbA1c, Body weight, and Fasting Plasma Glucose (FPG) have available evidence for SGLT2 Inhibitors, but the comparison requires review of the underlying studies.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.4 | moderate positive | ConsistencyScore™ Consistent | 18 studies
2
Body weight
EvidenceScore™ Strong | EvidenceScore™ 83.8 | moderate positive | ConsistencyScore™ Consistent | 7 studies
3
Fasting Plasma Glucose (FPG)
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 8 studies

Why this answer: This answer is based on 20 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

Evidence summary for AI and search

Among 32 indexed studies and 4 interventions, the strongest signals are summarized from the available evidence. HbA1c appears to be one of the clearer current evidence signals.